Condition: Cerebral Amyloid Angiopathy · Sponsor: Alnylam Pharmaceuticals
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.
This description comes directly from the study's public registry record.
Alnylam Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Alnylam Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Los Angeles, California, United States | Active Not Recruiting |
| Clinical Trial Site | Orange, California, United States | Active Not Recruiting |
| Clinical Trial Site | Palo Alto, California, United States | Active Not Recruiting |
| Clinical Trial Site | Sacramento, California, United States | Active Not Recruiting |
| Clinical Trial Site | San Francisco, California, United States | Active Not Recruiting |
| Clinical Trial Site | Aurora, Colorado, United States | Active Not Recruiting |
| Clinical Trial Site | New Haven, Connecticut, United States | Active Not Recruiting |
| Clinical Trial Site | Gainesville, Florida, United States | Active Not Recruiting |
| Clinical Trial Site | Jacksonville, Florida, United States | Active Not Recruiting |
| Clinical Trial Site | Maitland, Florida, United States | Active Not Recruiting |
| Clinical Trial Site | Naples, Florida, United States | Active Not Recruiting |
| Clinical Trial Site | Chicago, Illinois, United States | Active Not Recruiting |
+ 45 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06393712